What does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult…
What is Xeris Biopharma Holdings, Inc.'s P/E and P/B ratio?
Xeris Biopharma Holdings, Inc. has a P/E ratio of -108.6 and a P/B ratio of -203.41.
What is Xeris Biopharma Holdings, Inc.'s debt-to-equity ratio?
Xeris Biopharma Holdings, Inc. has a debt-to-equity ratio of 18.85.
How much does Xeris Biopharma Holdings, Inc. owe compared with what it owns?
Xeris Biopharma Holdings, Inc. owes $1.02 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Xeris Biopharma Holdings, Inc.'s Positivity rank?
Xeris Biopharma Holdings, Inc. is ranked #6,740 of 6,774 companies globally and #3,970 of 4,000 in United States on PositoAI, with a Positivity Score of -141,302.
Does Xeris Biopharma Holdings, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Xeris Biopharma Holdings, Inc..
Where can I read the latest news about Xeris Biopharma Holdings, Inc.?
Recent headlines about Xeris Biopharma Holdings, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Xeris Biopharma Holdings, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Xeris Biopharma Holdings, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.